Home›Trial›NCT04996875
🔬NCT04996875Phase 2RECRUITING

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Study Summary

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

Conditions
Advanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)Aggressive Systemic Mastocytosis (ASM)
Interventions / Drugs
bezuclastinib
View on ClinicalTrials.gov ↗
Sponsor
COGT
Cogent Biosciences
Precision Medicine
D45/100
Study Details
Enrollment140 participants
Primary Completion—
Lead SponsorCogent Biosciences, Inc.
Data Retrieved2026-04-11 04:10:18.672934+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.